{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:42:59Z","timestamp":1775907779715,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Introduction: The onset of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) is caused by acquired somatic mutations in target myeloid genes \u201cdriver mutations\u201d. The CCL2 gene is overexpressed by non-Hodgkin lymphomas and multiple solid tumors. Aim of the study: to evaluate the possible association of CCL2 rs1024611 SNP and its expression level and the risk of developing Philadelphia-negative MPNs. Patients and methods: A total of 128 newly diagnosed Philadelphia-negative MPN patient and 141 healthy subjects were evaluated for the genotype distribution of CCL2 rs1024611 and CCL2 expression levels. Results: The CCL2 rs1024611 G\/G genotype was more frequent and significantly frequent among PMF and Post-PV\/ET-MF patients and the mean CCL2 expression levels were significantly higher in PMF and Post-PV\/ET-MF compared to the healthy subjects. The CCL2 rs1024611 SNP was significantly correlated to the CCL2 gene expression level and fibrosis grade. ROC analysis for the CCL2 gene expression level that discriminates MF patients from PV + ET patients revealed a sensitivity of 80.43% and a specificity of 73.17% with an AUC of 0.919 (p &lt; 0.001). Conclusion: The CCL2 rs1024611 polymorphism could be an independent risk factor for developing MF (PMF and Post-PV\/ET-MF). Moreover, CCL2 gene expression could be potential genetic biomarker of fibrotic progression.<\/jats:p>","DOI":"10.3390\/genes13030492","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T11:46:47Z","timestamp":1646912807000},"page":"492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms"],"prefix":"10.3390","volume":"13","author":[{"given":"Hossam","family":"Hodeib","sequence":"first","affiliation":[{"name":"Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Abd EL Hai","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-0535","authenticated-orcid":false,"given":"Mohamed A","family":"Tawfik","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alzahraa A.","family":"Allam","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Selim","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah Ahmed","family":"Elsawy","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5249-6819","authenticated-orcid":false,"given":"Amira","family":"Youssef","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"ref_3","first-page":"E454","article-title":"The prognostic impact of bone marrow fibrosis in primary myelo-fibrosis","volume":"91","author":"Guglielmelli","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the international working group for myelofibrosis research and treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1038\/leu.2017.268","article-title":"Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A Gain-of-Function Mutation of JAK2in Myeloproliferative Disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"So-matic Mutations of Calreticulin in Myeloproliferative Neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of the myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofi-brosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"670580","DOI":"10.1155\/2015\/670580","article-title":"Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest","volume":"2015","author":"Mondet","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajh.21972","article-title":"Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.cca.2010.07.006","article-title":"MCP-1: Chemoattractant with a role beyond immunity: A review","volume":"411","author":"Yadav","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte Chemoattractant Protein-1 (MCP-1): An Overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.biocel.2008.07.018","article-title":"Monocyte chemoattractant protein-1: A key mediator in in-flammatory processes","volume":"41","author":"Melgarejo","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immu-notherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Iwamoto, H., Izumi, K., and Mizokami, A. (2020). Is the C-C Motif Ligand 2\u2013C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239328"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1744-313X.2008.00778.x","article-title":"TNF, IFNG, IL6, IL10 and TGFB1 gene polymorphisms in South and Southeast Brazil","volume":"35","author":"Visentainer","year":"2008","journal-title":"Int. J. Immunogenet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2007.03489.x","article-title":"The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility","volume":"150","author":"Colobran","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-018-0088-y","article-title":"The \u22122518 A\/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity","volume":"32","author":"Masselli","year":"2018","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neo-plasms and acute leukemia: Rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.smim.2018.10.011","article-title":"Aging, inflammation and cancer","volume":"40","author":"Bottazzi","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An Immune Dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Masselli, E., Carubbi, C., Pozzi, G., Percesepe, A., Campanelli, R., Villani, L., Gobbi, G., Bonomini, S., Roti, G., and Rosti, V. (2021). Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis. Cancers, 13.","DOI":"10.3390\/cancers13112552"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wong, W.J., Baltay, M., Getz, A., Fuhrman, K., Aster, J.C., Hasserjian, R.P., and Pozdnyakova, A. (2019). Gene expression profiling distin-guishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflam-matory signatures. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216810"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.aam7928","article-title":"Inflammation and metabolism in tissue repair and regeneration","volume":"356","author":"Eming","year":"2017","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.htct.2017.12.003","article-title":"Philadelphia-negative myeloproliferative neoplasms as disorders marked by cy-tokine modulation","volume":"40","author":"Cacemiro","year":"2018","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10204","DOI":"10.1038\/ncomms10204","article-title":"Epigenetic switch drives the conversion of fibro-blasts into proinvasive cancer-associated fibroblasts","volume":"6","author":"Albrengues","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"453020","DOI":"10.1155\/2015\/453020","article-title":"Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms","volume":"2015","author":"Diklic","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"415024","DOI":"10.1155\/2015\/415024","article-title":"Inflammation as a Keystone of Bone Marrow Stroma Al-terations in Primary Myelofibrosis","volume":"2015","author":"Desterke","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Masselli, E., Pozzi, G., Vaccarezza, M., Mirandola, P., Galli, D., Vitale, M., Carubbi, C., and Gobbi, G. (2020). ROS in Platelet Biology: Func-tional Aspects and Methodological Insights. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144866"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/3\/492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:34:38Z","timestamp":1760135678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/3\/492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["genes13030492"],"URL":"https:\/\/doi.org\/10.3390\/genes13030492","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]}}}